Jan. 6, 2023 — The highly anticipated Alzheimer’s drug lecanemab was granted accelerated approval status this afternoon by the FDA, offering hope where there has been little for patients and their families affected by the devastating disease.
More than 6 million people in the U.S. live with Alzheimer’s.
It’s not a cure, but the drug, given intravenously every 2 weeks, has shown moderate positive effects in clinical trials in slowing early-stage disease.
But many are wary. As explained in an editorial last month in the journal The Lancet, “The Alzheimer’s disease community has become accustomed to false hope, disappointment, and controversy.”
Some worry about lecanemab’s…
